论文部分内容阅读
目的:探讨125I粒子植入联合NP方案化疗治疗晚期非小细胞肺癌的临床价值。方法:36例晚期非小细胞肺癌分为两组,治疗组(A)采用CT引导下125I粒子植入,后行NP方案化疗,对照组(B)单纯行NP方案化疗,两组均为4个周期。结果::两组治疗后总有效率A组为79%,B组为50%,1、2 a生存率A组分别为66%和43%,B组分别为39%和21%,中位生存期A组18个月,B组11个月,二者有统计学差异(P<0.05)。结论:125I粒子植入联合NP方案化疗是治疗晚期非小细胞肺癌安全有效的治疗方法,值得临床进一步研究。
Objective: To investigate the clinical value of 125I particle implantation combined with NP chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: Thirty-six patients with advanced non-small cell lung cancer were divided into two groups. The treatment group (A) received CT guided 125I seed implantation followed by NP regimen and the control group (B) NP regimen alone A cycle. Results: The total effective rate in both groups was 79% in group A, 50% in group B, 66% and 43% in group 1,2, and 39% and 21% in group B, respectively The survival time was 18 months in group A and 11 months in group B, with statistical significance (P <0.05). CONCLUSION: 125I seed implantation combined with NP regimen is a safe and effective treatment for advanced non-small cell lung cancer and deserves further clinical study.